Physician profile
Xiaohong Si
NPI 1801089347
$1,323.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.33 · 2020: $476 · 2021: $353 · 2022: $269 · 2023: $125 · 2024: $26.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $227.48 | 2020-2021 | |
| Neuronetics, INC. | $136.22 | 2022 | |
| Baxter Healthcare | $132.63 | 2022 | |
| Kyowa Kirin, INC. | $124.94 | 2023 | Nourianz |
| Amgen INC. | $121.84 | 2020 | |
| Eisai INC. | $121.36 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.25 | 2020 | |
| Neurocrine Biosciences, INC. | $100.60 | 2021 | |
| Sk Life Science, INC. | $52.11 | 2021 | |
| Sunovion Pharmaceuticals INC. | $50.40 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $46.00 | 2021 | |
| Allergan, INC. | $44.43 | 2021 | |
| Ge Healthcare | $37.75 | 2019 | |
| Argenx US, INC. | $26.29 | 2024 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaohong Si listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.